Fresh off the research radar — new HBOT science just published, summarized for our community.
Title:
Case report shows shallow-dive HBOT resolved symptoms and normalized inflammation markers in a patient with CIRS
What this case report examined
Chronic Inflammatory Response Syndrome (CIRS) is a complex, multi-system illness often triggered by mold toxins or environmental exposures.
Patients typically experience:
- severe fatigue
- cognitive issues
- neurological symptoms
- immune dysregulation
- abnormal inflammatory markers
Standard treatments vary widely and often provide incomplete relief.
This 2025 case report documents the incidental discovery that low-pressure hyperbaric oxygen therapy may help regulate inflammation and improve function in CIRS.
HBOT protocol used
The patient completed:
- 40 sessions
- over 10 weeks
- using low-pressure “shallow dive” HBOT
The paper does not list the exact pressure, but “shallow dive HBOT” in the literature typically refers to 1.3 ATA or lower — the same range used in most mild HBOT chambers.
This makes the findings especially relevant for the mild-HBOT community.
Who was treated?
- 60-year-old female
- Persistent, multi-system symptoms
- Abnormal biomarkers (including TGF-β1 and MMP-9)
- Poor visual contrast sensitivity (VCS)
- History consistent with mold-related CIRS
She had ongoing symptoms despite multiple previous interventions.
Key improvements observed
1. All 22 symptoms resolved
The patient entered the study with a long list of physical, neurological and cognitive symptoms.
After 40 sessions, every single symptom resolved.
2. Huge improvement in visual contrast sensitivity (VCS)
VCS scores improved from:
- 68% → 93%
VCS is one of the hallmark tests used in mold and neurotoxin-related conditions.
3. Sharp reduction in inflammatory biomarkers
Blood markers associated with chronic inflammation decreased substantially, including:
- TGF-β1
- MMP-9
These biomarkers are often elevated in mold illness, Lyme-related inflammation and other environmental illnesses.
4. Improvements in cognition and fatigue
The patient reported:
- sharper thinking
- better focus
- improved mental stamina
- dramatic reduction in fatigue
5. Strong signal for immune regulation
HBOT appeared to modulate systemic inflammation at a whole-body level.
Why this matters
This case is important for several reasons:
1. It used low-pressure HBOT
Meaning the improvements occurred at mild HBO pressures, not high medical pressures.
2. CIRS is notoriously difficult to treat
Seeing complete symptom resolution is unusual and noteworthy.
3. Objective markers improved
This wasn’t just “feeling better” — labs, VCS testing and inflammation markers improved alongside symptoms.
4. It suggests HBOT may address core CIRS mechanisms
Including:
- hypoxic tissue stress
- mitochondrial dysfunction
- neuroinflammation
- immune dysregulation
5. It supports the role of mild HBOT for complex environmental illnesses
An area with very little published data until now.
Takeaway for the community
Low-pressure hyperbaric oxygen therapy:
- resolved all reported symptoms
- improved cognition and fatigue
- normalized visual contrast sensitivity
- reduced inflammatory markers like TGF-β1 and MMP-9
- enhanced overall systemic recovery
This case highlights HBOT’s potential as a safe, biologically meaningful therapy for CIRS and other complex inflammatory conditions, especially in mild-pressure settings.
HBOT Radar continues to follow new research on inflammation, environmental illness and whole-body immune recovery using hyperbaric oxygen.
Source: https://pubmed.ncbi.nlm.nih.gov/40837587/
